PMCB (PharmaCyte Biotech) 3-Year RORE % : -102.04% (As of Jan. 2025)

PharmaCyte Biotech 3-Year RORE % Chart

PharmaCyte Biotech Annual Data
	Trend	Apr15	Apr16	Apr17	Apr18	Apr19	Apr20	Apr21	Apr22	Apr23	Apr24
3-Year RORE %		Get a 7-Day Free Trial					-24.12	-24.92	-45.31	-65.34	35.13

PharmaCyte Biotech Quarterly Data
	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24	Apr24	Jul24	Oct24	Jan25
3-Year RORE %	Get a 7-Day Free Trial															3.58	35.13	-356.00	-136.21	-102.04

Competitive Comparison of PharmaCyte Biotech's 3-Year RORE %

For the Biotechnology subindustry, PharmaCyte Biotech's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

PharmaCyte Biotech's 3-Year RORE % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PharmaCyte Biotech's 3-Year RORE % distribution charts can be found below:

* The bar in red indicates where PharmaCyte Biotech's 3-Year RORE % falls into.

PharmaCyte Biotech 3-Year RORE % Calculation

PharmaCyte Biotech's 3-Year RORE % for the quarter that ended in Jan. 2025 is calculated as:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Jan. 2025 and 3-year before.

PharmaCyte Biotech  (NAS:PMCB) 3-Year RORE % Explanation

Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.

There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.

Be Aware

Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.

PharmaCyte Biotech 3-Year RORE % Related Terms

Thank you for viewing the detailed overview of PharmaCyte Biotech's 3-Year RORE % provided by GuruFocus.com. Please click on the following links to see related term pages.

PharmaCyte Biotech Business Description